Newly developed retatrutide, a twin -action treatment targeting equally GLP-1 and GIP receptors, is sparking considerable interest within the weight loss community. Preliminary clinical studies have revealed impressive decreases in body size and gains in physiological markers for people with overweight. Researchers believe this ground-breaking app